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Abstract
Purpose The purpose of this study was to investigate if a 2-
year intervention with a minimal resource fracture liaison ser-
vice (FLS) was associated with increased investigation and
medical treatment and if treatment was related to reduced re-
fracture risk.
Methods The FLS started in 2013 using existing secretaries
(without an FLS coordinator) at the emergency department
and orthopaedic wards to identify risk patients. All patients
older than 50 years of age with a fractured hip, vertebra, shoul-
der, wrist or pelvis were followed during 2013–2014
(n=2713) and compared with their historic counterparts in
2011–2012 (n=2616) at the same hospital. Re-fractures were
X-ray verified. A time-dependent adjusted (for age, sex, pre-
vious fracture, index fracture type, prevalent treatment, co-
morbidity and secondary osteoporosis) Cox model was used.
Results The minimal resource FLS increased the proportion
of DXA-investigated patients after fracture from 7.6 to 39.6 %
(p<0.001) and the treatment rate after fracture from 12.6 to
31.8 %, which is well in line with FLS types using the
conventional coordinator model. Treated patients had a 51 %
lower risk of any re-fracture than untreated patients (HR 0.49,
95 % CI 0.37–0.65 p<0.001).
Conclusions We found that our minimal resource FLS
was effective in increasing investigation and treatment,
in line with conventional coordinator-based services, and
that treated patients had a 51 % reduced risk of new
fractures, indicating that also non-coordinator based
fracture liaison services can improve secondary preven-
tion of fractures.
Keywords Efficiency . FLS . Fracture . Fracture liaison
service . Osteoporosis
Introduction
In Sweden, the fourth most important cause of illness is fall-
related injuries [1]. Falls often cause fractures, and the yearly
fracture-related cost of osteoporosis in Sweden has been esti-
mated to be €0.5 billion [2]. Fractures are common and dan-
gerous. At the age of 50, the risk of sustaining a fragility
fracture (i.e. a fracture caused by an injury that would be
insufficient to fracture a normal bone) during the remaining
lifetime is 50 % for women and 20 % for men [3]. Fragility
fractures are associated with an increased morbidity and mor-
tality, especially hip and vertebral fractures in which the risk of
mortality is twice as high for patients older than 80 years
compared to age-matched controls [4].
There is solid evidence that medical treatment of osteopo-
rosis reduces fracture rate in postmenopausal women, espe-
cially with low BMD and high fracture risk [5]. Alendronate
treatment leads to considerable relative risk reduction (RRR),
45 % for vertebral fractures and 40 % for hip fractures [6].
With a yearly dose of zoledronic acid, the RRR is even higher,
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70 % for vertebral fractures and 41 % for hip fractures [7].
Denosumab treatment has also proven effective to reduce frac-
ture risk. For women older than 75 years or with T-score <2.5
SD, the RRR for a hip fracture was 61%, and for patients with
multiple vertebral fractures, the RRR for subsequent vertebral
fracture was 55 % [8].
A patient with a prior fracture has an increased risk of a
new fracture [9]. For most fracture sites, the risk is doubled,
but a patient with a vertebral fracture has a 4-fold increased
risk of a new vertebral fracture [9]. In spite of well-
documented evidence for fracture preventingmedication, only
a minority receive medical treatment within 6–12months after
an osteoporotic fracture (14 % of Swedish women and 3 % of
men, aged 50 years or more) [10].
In an effort to increase the proportion of treated patients
after a fracture, structured prevention programs (fracture liai-
son services, FLS) have been introduced to identify, investi-
gate and reduce patients at risk of new fractures.
Demonstrably, FLS programs show an increase in the number
of patients investigated and treated [11, 12].
However, there are few studies attempting to report on the
FLS main objective, which is prevention of new fractures.
Furthermore, previously reported studies may raise quality
concerns [13–17]. Two studies created a control group from
the patients who chose not to participate in the FLS [13, 15].
Two other studies used another hospital without an FLS as a
control [16, 17]. Both approaches raise selection bias issues.
Three of the studies used questionnaires to record re-fractures
[13–15]. However, self-reported fractures have been associat-
ed with 11–29 % false positives [18–20] and 7 % false nega-
tives [19]. Thus, using this method to record fractures intro-
duces an error of the same magnitude as the expected effect
from treatment [6]. The previously reported studies only in-
cluded between 41 and 225 re-fractures.
The gold standard when introducing an FLS is to use a
coordinator to select patients and manage the patient flow
[21]. However, this would require specific additional funds
that may not be available at all hospitals. Therefore, we inves-
tigated an FLS without a coordinator, introduced with mini-
mal organisational changes. The aim of the performed study
was to investigate if a minimal effort FLS (2-year
intervention) was associated with increased investigation and




Skaraborg Hospital, a Swedish regional hospital covering
265,000 inhabitants, started an FLS on 1 January 2013 and
included all patients older than 50 years seeking care for an
osteoporotic fracture (defined as a fracture of the wrist, upper
arm, hip, vertebra or pelvis). The FLS comprised four steps.
1. Risk patient identification: A total of ∼30 secretaries at the
emergency department and the orthopaedic clinic were
responsible for identifying risk patients and order a bone
density measurement (DXA) and fracture risk (FRAX)
assessment based on ICD-10 fracture codes in the patient
charts. Patients with pathological fractures or who were
deceased prior to DXA referral were excluded.
2. DXA examination and FRAX assessment: Patients were
invited to the hospital’s DXA unit where experienced
nurses performed the DXA examination as well as a
FRAX assessment.
3. DXA and FRAX evaluation: Based on regional and na-
tional guidelines [22], an experienced endocrinology con-
sultant assessed the bone densitometry results and clinical
risk factors, defined a diagnosis and provided treatment
recommendation and follow-up advice, which were sent
to the patient’s primary care physician.
4. Treatment initiation: Based on the recommendation and in
consultation with the patient, the primary care physician
initiated treatment in order to reduce the risk for a new
fracture. The primary care physician was responsible to
rule out secondary osteoporosis and choose a suitable type
of osteoporosis medication.
Our FLS model had two key elements: the delegation of
referral power to secretaries and the detailed consultant re-
sponse, the former to enable organisational stability and ro-
bustness and the latter to reduce the workload for the receiving
doctor.
During the first year, 2013, patients’ relatives or staff at
nursing homes often cancelled the examination due to per-
ceived high patient age or morbidity. This leads to a relatively
high DXA cancellation rate among the elderly, 50 % for pa-
tients over 80 years compared to 23 % for 50–79 years
(p<0.001). By cancelling the DXA, the patient also lost the
possibility of being eligible for treatment through the FLS.
Therefore, starting January 2014, the hospital decided to offer
treatment with a yearly intravenous infusion of zoledronic
acid (5 mg) to all patients older than 80 years with a hip
fracture, without prior DXA examination.
Study design
The potential FLS effect was investigated comparing the in-
tervention period, 2013–2014, with the control period, 2011–
2012. All patients older than 50 years with an index osteopo-
rotic fracture, the types targeted by the FLS, were included in
the study. Patients with the selected fracture types represented
56 % of all fractured patients. The intervention group
consisted of patients presenting with an osteoporotic fracture
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during 2013–2014 (n=2616), i.e. when the FLS had started.
The control group consisted of historical controls 2011–2012
(n=2713). The follow-up time varied from 0 to 2 years, i.e.
each period was truncated at 31 December 2012 and 2014
respectively in order to achieve group symmetry and to avoid
crossover effects. In order to assess potential fracture risk re-
duction frommedical treatment, all treated patients, regardless
of period, were compared with the non-treated patients.
Subgroup analysis was performed on hip fracture patients
above 80 years of age since they were handled slightly differ-
ently in the process.
Definition of variables
In this study, the term fracture refers to a fracture event, i.e.
one or more fractures at the same occasion, with an ICD-10
diagnosis that starts with S12, S22, S32, S42, S52, S62, S72,
S82, S92, T02, T08, T10, T12, T142 or M485. If a secretary
sent a referral for DXA as instructed, it was automatically
registered in the digitalized patient record. The age was set
at the time of the index fracture, and gender was derived from
the patient’s social security number.
The follow-up time in the study was calculated from the
fracture date (or if the patient was admitted, from the date of
discharge) to the actual event, where event refers to DXA
scan, medical treatment, a subsequent fracture or death, de-
pending on analysed outcome. The follow-up time was trun-
cated if a patient moved from the region, died or if the follow-
up period ended.
Previous fracture was defined as any other fracture before
the date of the index fracture, stretching exactly 14 years back
in time.
Three types of prevalent medications were accounted for:
(i) active medical treatment for osteoporosis, (ii) calcium and/
or vitamin D and (iii) glucocorticoids. Prevalent active medi-
cal treatment for osteoporosis was included as number of days
during the year prior to fracture with bisphosphonates,
denosumab, strontium ranelate or hormonal treatment (p.o.
or transdermal). Similarly, a separate variable was calculated
for calcium and/or vitamin D. Prevalent glucocorticoid treat-
ment was defined as milligrams of prednisolone equivalents
during the year prior to fracture. The Prednisolone equivalents
were calculated using conversion factors: betamethasone
(8.33), dexamethasone (6.67), methylprednisolone (1.25), hy-
drocortisone (0.25) and cortisone (0.2).
Incident medical treatment was defined as number of days
of treatment, which started at the first date of medication re-
trieval from the pharmacy after the index fracture and ended
when prescription ended, a subsequent fracture or death oc-
curred or if the patient moved out of the area. For prescription
medication, treatment refers to the patient retrieving medica-
tion at the pharmacy whereas parenteral treatment adminis-
tered at the hospital was registered in the patient’s record.
Categorical variables were created for prevalent illnesses, if
the ICD-10 diagnosis was present in the hospital records with-
in 10 years prior to index fracture. The illnesses included
osteoporosis with or without fracture, rheumatoid arthritis
and all diagnoses with prevalence higher than 5 % that might
correlate with fracture risk. We also created a variable for
secondary osteoporosis according to FRAX and all its com-
ponents (insulin-dependent diabetes, hyperthyroidism,
hypogonadism, malnutrition, osteogenesis imperfecta or
chronic liver disease). A modified Charlson comorbidity in-
dex was used to summarize and quantify comorbidity. The
index was calculated as a sum of the following diseases,
ICD-10 codes in parenthesis: one point each for an ischaemic
heart disease (I20–I25); congestive heart failure (I50); cere-
brovascular disease (I60–I69); disease of arteries, arterioles
and capillaries (I70–I79); diabetes (E10–14); dementia
(F00–F03); chronic pulmonary disease (J43–J46); and chronic
liver disease (parts of K70–K77); two points each for renal
failure (N17–N19), hemiplegia (G81); lymphoma or leukemia
(C81–C96); and tumor without metastasis (C00–C76, C80,
C97, 5-year history); and six points for metastatic solid tumor
(C77–C79)—10-year history if not stated otherwise.
Statistics
Chi-square tests were used on categorical variables in order to
investigate statistical differences between the control and in-
tervention groups in terms of comorbidity, previous medica-
tions and known risk factors. Differences between the contin-
uous variables were investigated using t test. A Cox propor-
tional hazard regression model was used for time-dependent
analysis. When DXA or treatment was the outcome, adjust-
ment was made only for age and gender (crude). When
analysing risk of new fracture or death, adjustment was also
made for previous fracture, index fracture type (hip fracture,
vertebral fracture or other), prevalent medical treatment, prev-
alent calcium or vitamin D treatment, prevalent glucocorticoid
treatment, prevalent osteoporosis diagnosis, rheumatoid ar-
thritis and secondary osteoporosis according to FRAX as well
as a modified Charlson morbidity index (fully adjusted). A p
value less than 0.05 was considered significant.
Statistical power calculation
The primary aim was to study the FLS effect on DXA utiliza-
tion and treatment rates. Assuming 1500 osteoporotic frac-
tures occur in Skaraborg per year, the mean follow-up time
in this 2-year study is 1 year (different starting points, fixed
end-point). Approximately 14 % receive treatment after frac-
ture [10]. Assuming an alpha-value of 0.05, any postinterven-
tion treatment rate above 16 % would render a power above
80 %. Since DXA measurements in most cases precede treat-
ment, we expect to find similar or larger increases in DXA
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utilization and therefore increased statistical power for this
end-point.
Regarding re-fractures in approximately 3000 patients in
each group, mean follow-up time of 1 year, assuming an
alpha-value of 0.05, an annual 8 % re-fracture rate without
treatment, an increase from 14 to 50 % in treatment rates
and a 50 % reduction of re-fractures from treatment would
render a statistical power of 82 %. However, assuming a 4-
month average delay from index fracture to start of treatment,
the statistical power falls to 51 % for the re-fracture end-point.
Assessment of BMD
Assessment of BMD (aBMD, g/cm2) was measured at the hip,
femoral neck and lumbar spine (L1–L4) using a Lunar
Prodigy (GE Healthcare). The same DXA machine was used
for all measurements. The coefficients of variations (CV)
ranged from 0.7 to 1.5 %.
Information sources
The hospital’s digitalized patient records were used to identify
patients with fractures during 2011–2014. In order to differ
records of re-visits regarding an old fracture from records of
new fractures, manual verification was performed. If a patient
had fracture entries on more than one occasion, that patient’s
hospital record was reviewed and only entries representing
true fracture occasions were kept. Thus, all re-fractures were
manually verified in the patient’s hospital records.
Information on the identified cohort concerning previous
fractures, current and previous diseases and medication as
well as date of DXA examination was also collected from
the hospital’s patient records. Date of death and moving in




A total of 5329 patients were included in the study, with 2616
in the intervention group and 2713 in the control group. The
accumulated follow-up time was 5014 years, with 2481 years
in the intervention group and 2534 years in the control group.
The mean follow-up time (mean ± SD) was 344 days (346
±219 days in the intervention versus 341±221 days in the
control group, p=0.39).
Baseline characteristics
Baseline characteristics are presented in Table 1. Apart for
slightly less patients with hypertension in the intervention
group, there were no significant differences between the inter-
vention group and the control group with regard to sex, age,
proportion of previous fracture, prevalence of osteoporosis,
rheumatoid arthritis, secondary osteoporosis according to
FRAX, modified Charlson comorbidity index, other possible
fall- or fracture-related diseases with prevalence above 5 % or
type of index fracture (Table 1).
In the subgroup hip fracture patients above 80 years, the
intervention group was slightly less inclined to have previous
glucocorticoid treatment, but otherwise no significant differ-
ences were observed (Table 1).
In the group selected for treatment, the prevalence of pre-
vious fracture was higher, as well as the proportion of women
and vertebral index fracture, than in the untreated group
(Table 1). Patients selected for treatment were slightly health-
ier according to Charlson (Table 1) and less prone to have
dementia (2.1 versus 4.0 %, p<0.01) than their untreated
counterparts were. Also, patients selected for treatment were
more inclined to already have treatment for osteoporosis as
well as glucocorticoid treatment (Table 1).
FLS patient identification
Of all the osteoporotic fractures in 2013–2014, 11 % were
omitted by the system, i.e. occurring in a unit with no FLS
secretary. Of the patients treated at an FLS unit, the secretaries
identified 75 % of the defined osteoporotic fractures.
Admitted patients had a higher likelihood of being included
than did patients visiting the emergency room (88 versus
61 %, p<0.001). The likelihood of being included also dif-
fered by index fracture type: hip 92 %, vertebral 60 %, wrist
76 %, shoulder 55 % and pelvic 67 % (p<0.001).
Increased likelihood of DXA examination
The proportion of patients being examined with DXA after a
fracture increased from 7.6 % in the control period to 39.6 %
in the intervention period (p<0.001). The time to DXA ex-
amination (mean ± SD) after index fracture decreased from
133±119 to 85±67 days (p<0.001), and the patients exam-
ined had no statistical difference in terms of femoral neck
BMD (0.72 ± 0.13 versus 0.73 ± 0.13, p= 0.36). Age- and
sex-adjusted time-dependent Cox regression analysis of the
intervention period versus the control period showed a 7-
fold increased likelihood of being examined with a DXA
(HR 7.0, 95 % CI 6.0–8.1 p<0.001) in the intervention period
(Fig. 1a). These results were highly similar when fully adjust-
ed (HR 7.1, 95 % CI 6.1–8.2, p<0.001).
Increased likelihood of medical treatment
There was no significant difference in prevalent osteoporosis
treatment rates between the control (9.2 %) and the
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intervention period (9.7 %). While the treatment rate after a
fracture only increased to 12.6 % (n=341) in the control pe-
riod, it increased to 31.8 % (n=833) in the intervention period
(p<0.001). Excluding patients with previous treatment, there
was no significant difference in time to treatment (mean ± SD)
in the control period (123±115 days) compared to the inter-
vention period (118 ± 79), p=0.33. Age- and sex-adjusted
time-dependent Cox regression analysis of the intervention
period versus the control period revealed a 2.8-fold increased
likelihood of being treated (HR 2.8, 95 % CI 2.5–3.2,
p<0.001, Fig. 1b). These results were highly similar when
fully adjusted (HR 2.6, 95 % CI 2.3–2.9, p<0.001). A break-
down of types of treatment showed that the proportion of
zoledronic acid and denosumab increased dramatically in the
intervention group (Table 2).
Re-fractures
There were a total of 469 new fractures in 444 patients, and the
most common re-fracture site was the hip (Table 3). There was
no significant difference in re-fracture rate in the control peri-
od compared to the intervention period—228 (8.4 %) versus
216 (8.3 %), p=0.85. Time to new fracture (mean ± SD) was
207±168 days in the control and 200±163 in the intervention
period, p=0.66. Using a time-dependent Cox analysis, the
risk reduction was also non-significant (crude HR 0.95,
95 % CI 0.79–1.14, p=0.59, and fully adjusted HR 0.95,
95 % CI 0.79–1.14, p=0.60).
Deaths
There was no significant difference in mortality rate in the
control period compared to the intervention period: 361
(13.3 %) versus 320 (12.2 %), p=0.24. Time to death (mean
± SD) was 178±169 days in the control and 186±162 in the
intervention period, p=0.56. A time-dependent Cox analysis
showed that the mortality in the intervention group tended to
be lower, but the reduction was not statistically significant
(crude HR 0.87, 95 % CI 0.75–1.01, p=0.07, and fully ad-
justed HR 0.88, 95 % CI 0.76–1.03, p=0.11).
Subgroup analysis
In hip fracture patients older than 80 years, the ratio of DXA
measurement after index fracture increased from 1.0 to 26.1%
or using a Cox proportional hazard analysis adjusted for age
and sex, which is a 32-fold increased likelihood (HR 32.4,
95 % CI 14.3–73.3, p<0.001).
The chance of receiving medical treatment increased from
8.4 to 28.3 %, or using Cox proportional hazard analysis ad-
justed for age and sex, which is a 3.9-fold increased likelihood
(HR 3.9, 95 % CI 2.8–5.4, p<0.001). Just like for the whole
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was no difference in time to treatment (mean ± SD), 127
±119 days in the control versus 105±47 days in the interven-
tion group, p=0.24.
Regarding re-fractures, there was no significant difference
in time to new fracture, 174±168 days versus 160±152 days
(p=0.66), but a significant reduction in re-fracture rate from
11.9 to 7.8 % (p=0.02) was observed comparing the control
and FLS periods. Using the time-dependent Cox model ad-
justed for age and sex, the FLS period was associated with a
35 % reduction of re-fracture rate (HR 0.65, 95 % CI 0.45–
0.95, p=0.03). This reduction was similar (HR 0.65 95 % CI
0.44–0–94, p=0.02) when fully adjusted.
Treated patients had reduced risk of re-fracture
Regardless of period, the treated patients had a significantly
lower fracture rate versus the non-treated patients (6.6 versus
8.8 %, p=0.02) as well as longer mean time to new fracture,
294 days versus 185 days (p<0.001). Using a time-dependent
Cox model, treated patients had a 40 % reduction of risk for
new fracture (crudeHR 0.60, 95%CI 0.47–0.77, p<0.001) or
51 % after adjustments for covariates (HR 0.49, 95 % CI
0.37–0.65, p<0.001, Fig. 2) than did untreated patients.
Using a fully adjusted Cox analysis, the risk reduction of
specific future fractures was even higher: for hip fractures
64 % (p<0.01), for vertebral fracture 73 % (p<0.01), for
major osteoporotic fractures 67 % (p<0.001) and for patients
with multiple future fracture events 63 % (p=0.047). In the
subgroup of patients older than 80 years, the risk reduction
was slightly higher than for the treated group as a whole, 54%
(p<0.001) (Table 4).
Mortality
The association between the Charlson comorbidity index and
mortality was analysed using a time-dependent Cox





















































Fig. 1 Follow-up after index
fracture. Periods 2011–2012 (no
FLS) versus 2013–2014 (FLS). a
DXA examination, b
pharmacological treatment.
Adjusted for age and sex
Table 2 Pharmacological treatment
Beforea index fracture Afterb index fracture




194 (7.2 %) 173 (6.6 %) 281 (10.4 %) 641 (24.5 %)
Zoledronic acid 3 (0.1 %) 8 (0.3 %) 3 (0.1 %) 83 (3.2 %)
Denosumab (Prolia) 6 (0.2 %) 10 (0.4 %) 8 (0.3 %) 38 (1.5 %)
All hormonal treatment, excl. vaginals 46 (1.7 %) 64 (2.4 %) 30 (1.1 %) 27 (1 %)
Strontium ranelate (Proteolos) 0 (0 %) 0 (0 %) 1 (0 %) 1 (0 %)
Teriparatid (Forsteo) 0 (0 %) 0 (0 %) 0 (0 %) 1 (0 %)
Total active osteoporotic treatment 249 (9.2 %) 255 (9.7 %) 323 (11.9 %) 791 (30.2 %)
No treatment 2464 (90.8 %) 2361 (90.3 %) 2390 (88.1 %) 1825 (69.8 %)
Number of patients 2713 2616 2713 2616
aOne year prior to fracture
b After index fracture but before potential re-fracture
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regression, adjusted for sex and age with death as outcome.
For each increased point in Charlson, the mortality was in-
creased by 30 % (HR 1.30, 95 % CI 1.21–1.39, p<0.001).
The mortality rate was significantly lower in the treated group
compared to the untreated group (6.4 versus 14.5 %,
p<0.001), and the mean time to death was longer in the treat-
ed group compared to the untreated group (244 versus
175 days, p<0.01). Time-dependent Cox analysis showed
that the treated group had a 56 % (crude HR 0.44, 95 % CI
0.34–0.56, p<0.001) or 66 % (fully adjusted HR 0.34, 95 %
CI 0.25–0.44, p<0.001) lower risk of mortality than did un-
treated patients.
Discussion
This study shows a remarkable 7-fold increase in patients
receiving DXA examination as well as a 2.8-fold increased
chance of receiving pharmacological osteoporosis treatment
as a result of a minimal resource (non-coordinator-based)
FLS. Patients receiving osteoporosis medication had a 51 %
lower re-fracture rate. With a re-fracture rate of 8.8 % for the
untreated, treatment was associated with an absolute risk re-
duction (ARR) of 4.5 %, which translates to 66 prevented
fractures per year in our total population sustaining a total of
1332 fractures yearly.
The reduction of re-fracture risk in the intervention group
was not significant for the study as a whole, but in the sub-
group of hip fracture patients older than 80 years, the FLS was
associated with a 35 % significantly lower re-fracture risk.
During the second year (2014) the FLS was used, these pa-
tients were able to receive zoledronic acid treatment (at the
hospital or in their homes) without prior DXA assessment,
which increased the proportion receiving treatment even fur-
ther. FLS patients in this category had a lower proportion of
prevalent glucocorticoid treatment, but were similar to con-
trols in regard to comorbidity, prevalent fracture and other
medical treatments. Even though the FLS was associated with
a reduced re-fracture rate in Cox models adjusted for gluco-
corticoid use and other covariates, it cannot be ruled out that
the selection of patients contributed to the association. A post
hoc power analysis based on actual risk reduction from 11.9 to
7.8 % using an alpha-value of 5 % revealed a statistical power
of 89 % in this particular subgroup.
Themortality rate among the patients with a re-fracture was
16.6 versus 12.5 % among patients without a re-fracture, in-
dicating a relationship between re-fracture and mortality.
However, when comparing the treated patients with the un-
treated, the reduction in mortality (66 %) was greater than the
reduction in re-fracture (51 %), even after adjustment for sex,
age, comorbidity, previous illnesses and medication. As ex-
pected, the Charlson comorbidity index was associated with
mortality. However, the large mortality risk reduction in pa-
tients selected for medical treatment suggests that treated pa-
tients were healthier, although we could not account for this
using our available data. In a meta-analysis of randomized
controlled trials, osteoporosis treatment has been shown to
reduce mortality by 11 % [23].
In our hospital, there is no specific department for osteopo-
rosis patients, which is partly why the distributed secretary-

























Fig. 2 Cumulative incidence of any re-fracture. Period 2011–2014. Non-
treated versus treated. Adjusted for age, sex, previous fracture, previous
osteoporosis, previous treatment, Charlson comorbidity index, secondary
osteoporosis according to FRAX, rheumatoid arthritis and type of index
fracture
Table 3 Re-fractures
Re-fracture site Number (%)
Hip 133 (28 %)
Vert 64 (14 %)
Wrist 56 (12 %)
Pelvic 54 (11 %)
Shoulder 34 (7 %)
Lowerleg 31 (7 %)
Distal femur 19 (4 %)
Costal 16 (3 %)
Elbow 13 (3 %)
Finger 8 (2 %)
Hand 8 (2 %)
Toe 7 (1 %)
Clavicle 7 (1 %)
Other 19 (4 %)
Number of re-fractures 469 (100 %)
Patients with multiple re-fracture sites 25
Number of patients with re-fractures 444
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based model was chosen instead of a central coordinator-
based model, which would have been more exposed to
organisational changes and required additional staff. If all
types of fractures would have been included in the FLS, we
speculate that the secretaries’ ability to recall and identify
patients to refer to DXAwould increase, which could possibly
have reduced the 25 % omitting rate.
To compare our minimal resource FLS with a conventional
coordinator-based FLS, the only procedure that differs is pa-
tient identification. Even though our FLS required no addi-
tional staff, our model required an estimated 5 min of extra
secretarial time per patient, both for identification and inves-
tigating if the patient was recently examined. Altogether, the
estimated additional time spent by the secretaries to carry out
these tasks amounted to approximately ten work days per year.
Since the effect of medication on fracture risk is undisput-
ed, it seems unethical to design randomized studies for eval-
uation of FLS programs. Ganda et al. [12] summarised the
evidence of the effectiveness of different FLS and graded
them depending on the degree of involvement: if an osteopo-
rosis unit both investigated and treated (type A), if an osteo-
porosis unit investigated but sent treatment recommendations
to the primary care physician (type B), if the hospital informed
the primary care physician of the fracture episode (type C) or
if the hospital informed the patient of being at risk for a re-
fracture and should become investigated (type D). Our FLS
mostly resembled a type B FLS, but since a proportion of
patients were treated by the hospital staff, the FLS to some
extent resembled a type A service. Type B FLS models were
able to increase DXA utilization from 9 to 59 % [12]. Our
minimal resource FLS increased the utilization rates from 8 to
40 %. However, the follow-up data of the late participants in
the study were truncated at the end of the period. If only
looking at 2011 participants versus those in 2013, the increase
was larger, from 9 to 50 % (p<0.001), thus almost as good as
a typical type B model. When comparing the ability to get
patients to treatment, our minimal effort FLS increased from
13 % (2011–2012) to 32 % (2013–2014) (p<0.001) or from
14 % (2011) to 39 % (2013) (p<0.001). This is an increase
well in line with the type B FLS increase from 20 to 41 %
(p=0.01) and almost as efficient as a type A service, increas-
ing treatment from 18 to 46 % (p<0.001) [12].
In 2008, Dell et al. described the Kaiser Southern
California Healthy Bones Program, a comprehensive program
including 620,000 patients, and showed a 37 % average re-
duction in hip fracture rate from 2006 versus an expected rate
based on age-adjusted hip fracture rates from 1997 to 1999
[24]. Lih et al. [13] described a 4-year prospective study with
1544 patients in Sydney, Australia, and reported an 80 % re-
duction of risk of further fracture. Controls, however, were
chosen from the group that chose not to attend the FLS, which
introduces potential selection bias issues. As opposed to Lih
et al., we used historical controls. In Lund, Sweden, Åstrand
et al. [14] reported a 42% risk reduction in a screened group in
a 6-year follow-up of 592 fracture patients 50–75 years of age
with a major osteoporotic fracture. However, a time-
dependent Cox model was not used and there were cross-
over effects from the control to the intervention group.
Furthermore, a questionnaire was used to register re-fractures,
with a response rate of 77 %, and self-reported fractures are
known to be associated with uncertainty [18–20]. In the pres-
ent study, we used a time-dependent Cox model, truncated the
follow-up in order to avoid cross-over effects and used man-
ually verified X-ray records for re-fracture reporting.
Huntjens et al. [16] in the Netherlands compared patients
with non-vertebral fractures presenting at a hospital with FLS
Table 4 Time-dependent Cox regression for treated versus non-treated on specific fracture events
Age at index fracture Follow-up event Number of re-fractures Adjustmenta Risk reduction HR 95 % CI
Above 50 Any new fracture 444 Crude 40 % 0.60 (0.47–0.77)
Adjusted 51 % 0.49 (0.37–0.65)
Above 50 Any new fracture and thereafter
at least one more fracture event
47 Crude 54 % 0.46 (0.2–1.1)
Adjusted 64 % 0.37 (0.14–0.99)
Above 50 Major osteoporotic fractureb 279 Crude 59 % 0.41 (0.28–0.59)
Adjusted 67 % 0.33 (0.22–0.51)
Above 50 Vertebral fracture 64 Crude 48 % 0.52 (0.25–1.05)
Adjusted 73 % 0.27 (0.12–0.61)
Above 50 Proximal femur fracture 133 Crude 67 % 0.33 (0.18–0.6)
Adjusted 64 % 0.36 (0.19–0.68)
Above 80 Any new fracture 287 Crude 42 % 0.58 (0.42–0.81)
Adjusted 54 % 0.46 (0.32–0.67)
a Crude = adjusted for age and sex. Adjusted = adjusted for age, sex, previous fracture, previous osteoporosis, previous treatment, Charlson comorbidity
index, secondary osteoporosis according to FRAX, rheumatoid arthritis and type of index fracture
b Fractured hip, vertebra, wrist or shoulder
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(n=1412) with ditto patients at a neighbouring hospital with-
out FLS (n=1910). There was no difference in re-fracture rate
after 2 years (6.7 versus 6.8 %), but a time-dependent Cox
model showed a 56% reduction of non-vertebral fractures and
a 35 % reduction of mortality, but the result could have been
affected by the differences in population demographics be-
tween the two hospitals. Van Der Kallen et al. [15] compared,
in a 2-year follow-up, 214 FLS patients with 220 patients who
had chosen not to participate in the FLS, did not adjust for
mortality and used a questionnaire to report rate of re-fracture
and found a reduction of fracture rate from 16.4 to 5.1 %.
Choosing non-participants as controls exposes the result for
a potential selection bias.
In 2015, Nakayama et al. reported a 30 % reduction in re-
fracture rate over a 3-year follow-up period when comparing
an FLS hospital with a non-FLS hospital [17]. However, the
hospitals had different sizes and treated somewhat different
patient groups, indicating possible problems of selection bias.
Furthermore, the fact that the number of re-fractures was quite
few suggests inadequate statistical power. Our study was per-
formed in the same hospital with historical controls. Apart
fromNakayama’s study, the above studies [13–16, 24] includ-
ed patients actually participating in an FLS program whereas
our study included all potential patients being eligible and
compared data from the FLS period with a historic period,
minimizing the risk of selection bias. In our study, 68 % of
the patients offered participation accepted a DXA examination
and/or medication.
Lih et al. showed that the FLS association with re-fracture
rate remained significant in the elderly when calculating sep-
arately for patients above and below 70 years of age [13]. Our
study demonstrates that osteoporosis treatment was associated
with equal or greater relative risk reduction in patients older
than 80 years of age than in all treated patients in the study, 54
versus 51 %.
Thus, several previous studies [13–15, 17, 24] have report-
ed that an FLS is associated with reduced fracture rates, but
many studies suffer from different quality issues and lack
power calculations. Using a post hoc power analysis on re-
ported re-fracture rate in the control versus the intervention
group, most studies [13–15, 17] appear to have sufficient
power (73–100 %). However, even with high power, the re-
sults could be affected by quality issues such as uncertainty
regarding self-reported re-fractures, differences in demo-
graphics between control and intervention hospitals or selec-
tion bias when using no-shows as control. Therefore, it could
be of interest to reassess the post hoc power analysis, but
instead use a prediction model for re-fracture rates in the
FLS. Assuming that the re-fracture rates of the control group
were true, the re-fracture rates of the intervention group can be
calculated based on reported treatment rates (if not reported,
10 % in the control group versus 50 % in the FLS were as-
sumed) and a 50 % fracture risk reduction from treatment.
Using these assumptions, the statistical power of the previous
studies would range from 7 to 54 % [13–17], while our study
reaches 51 %. Assuming a 4-month delay before the patient is
likely to receive treatment after index fracture resulted in fur-
ther reduced statistical power to between 7 and 39 % for the
previous studies and to 24% in our study. Persistence rates are
not included in the model, which are known to be low, around
50 % [25], which would decrease the difference in re-fracture
rate and reduce the expected power even further. Thus, all yet
existing studies investigating re-fracture reduction by FLS,
including the present study, appear to be underpowered.
The present study investigating a minimal resource
FLS, implemented using already existing staff, clearly
demonstrates large effects in increasing DXA investiga-
tion and treatment rates. Among the strengths of our
study is the fact that it covers a large patient group
(n= 5329) with comprehensive background data on co-
morbidities and medications. The manual verification of
the registers using patient charts and X-ray reports
strengthens the quality of re-fracture data and offers a
reliable re-fracture rate. Also, clinical vertebral fractures,
often omitted in other studies, were included in our
study. Furthermore, our control group is clearly defined
with the same patient category from the same hospital
and patient preference was not an inclusion factor.
Conclusions
We conclude that a minimal resource FLS increased the num-
ber of fracture patients being DXA-examined and treated, re-
sembling increases observed in coordinator-based FLS
models. Patients receiving osteoporosis medication had re-
duced risk of any major osteoporotic, vertebral and hip frac-
ture. Furthermore, the studied FLS was related to reduced re-
fracture rate in hip fracture patients 80 years or older, but this
result could have been affected by insufficient statistical pow-
er in the analysis.
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